For subscribers
Shifting cancer care back to public hospitals is no cure
Expensive or unapproved drugs are a headache in the new cancer drugs policy. Here’s how to let the private sector have a viable supporting role.
Sign up now: Get ST's newsletters delivered to your inbox
The writer notes that at least two issues have emerged in the heated discussion about the Cancer Drug List.
PHOTO: ST FILE
Wee Hwee Lin
Follow topic:
There has recently been a flurry of articles and forum letters in The Straits Times discussing the impact of a new Cancer Drug List policy on patients with cancer.
It comes into effect in September for people with MediShield Life and for MediSave withdrawals, and in April next year for those with Integrated Shield Plans (IPs).
